Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis
作者:Jean-Guy Boiteau、Gilles Ouvry、Jean-Marie Arlabosse、Stéphanie Astri、Audrey Beillard、Yushma Bhurruth-Alcor、Laetitia Bonnary、Claire Bouix-Peter、Karine Bouquet、Marilyne Bourotte、Isabelle Cardinaud、Catherine Comino、Benoît Deprez、Denis Duvert、Angélique Féret、Feriel Hacini-Rachinel、Craig S. Harris、Anne-Pascale Luzy、Arnaud Mathieu、Corinne Millois、Nicolas Orsini、Jonathan Pascau、Artur Pinto、David Piwnica、Gaëlle Polge、Arnaud Reitz、Kevin Reversé、Nicolas Rodeville、Patricia Rossio、Delphine Spiesse、Samuel Tabet、Nathalie Taquet、Loïc Tomas、Emmanuel Vial、Laurent F. Hennequin
DOI:10.1016/j.bmc.2017.07.054
日期:2018.2
in-house research programs. In this article, we present the discovery of clinical candidate 26a. Starting from hits plagued with poor solubility or genotoxicity, 26a was identified through thorough multiparameter optimisation. Showing robust in vivo activity in an oxazolone-mediated inflammation model, the compound was selected for development. Following a polymorph screen, the hydrochloride salt was
靶向TNFα途径是治疗牛皮癣的有效方法。在这一途径中,TACE成为可药物治疗的目标,并且一直是内部研究计划的重点。在本文中,我们介绍了临床候选药物26a的发现。从溶解度或基因毒性差的命中开始,通过彻底的多参数优化确定了26a。在恶唑酮介导的炎症模型中显示出强大的体内活性,因此选择了该化合物进行开发。经过多晶型物筛选后,选择盐酸盐,并有效地进行了合成,以API的总收率达到47%。